Drug Profile

ARX 305

Alternative Names: ARX-305; JNJ-0631; NCB-002

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ambrx
Developer Ambrx; NovoCodex Biopharmaceuticals
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action CD70 antigen inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Renal cancer; Solid tumours
No development reported Multiple myeloma

Most Recent Events

28 Apr 2025 Phase-I clinical trials in Renal cancer (Second-line therapy or greater, In adults) in USA (Parenteral), prior to April 2025 (Janssen Research & Development pipeline, April 2025) (ARX305-01)
07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
08 Jan 2024 Preclinical development in Renal-cancer is still ongoing in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com